Research & Impact
Precision Health Economics employs novel approaches to generate rigorous evidence quantifying the value of innovative therapeutic advances to reach payers, healthcare providers, policymakers, and other interested stakeholders.
PHE has a track record of publishing in leading peer-reviewed journals and scientific conferences spanning multiple disciplines including health policy, economics, and medicine. PHE has also collaborated with clients to arrange coordinated research initiatives. These initiatives have included policy events in Washington, DC, as well as special issues of leading journals such as Health Affairs and the American Journal of Managed Care to highlight broader themes across research studies.
Examples of how PHE has generated impact for its clients are provided in the following case studies, showcasing the diversity of PHE’s capabilities.
Patient and physician treatment preferences in atrial fibrillation
Numerous treatment options are available for non-valvular atrial fibrillation (NVAF) patients, each offering a different combination of associated attributes, such as stroke risk, bleeding risk, and convenience.
Modeling the potential societal value of precision medicine
Precision medicine involves the identification of subgroups of patients, through biomarkers or other means, in order to identify the most effective interventions for an individual patient, which can include treatment and prevention strategies.
The insurance value of multiple sclerosis treatments
Multiple sclerosis exerts a high burden on patients and caregivers. A manufacturer was concerned that existing economic evaluations of multiple sclerosis therapies omitted a substantial share of the value these treatments provide to patients and society more generally.
Implications of non-distinguishable biosimilar names
Over the past several years, the FDA has approved the first biosimilar treatments as lower-cost alternatives to biologic (large-molecule) therapies. In contrast to generic formulations of small-molecule treatments, biosimilars are not necessarily structurally identical to their reference products, due to the complexity of biologics and their manufacturing processes.
Long-term impact of broad treatment with hepatitis C cures
A manufacturer was interested in presenting rigorous evidence to insurers and policymakers to quantify the long-term value of hepatitis C virus (HCV) therapies, which have cure rates of over 90% but have generated controversy over their pricing.